CYC.AX ASX
Cyclopharm Limited
1W: -2.2%
1M: -13.7%
3M: -4.3%
YTD: -52.7%
1Y: -53.9%
3Y: -83.4%
5Y: -82.8%
A$0.44 ($0.31)
+0.00 (+0.00%)
Weekly Expected Move ±9.6%
A$0
A$0
A$0
A$0
A$1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$32M
+17.2% ▲
5Y CAGR: +17.1%
Gross Profit
-$1M
-108.1% ▼
Operating Income
-$18M
-26.7% ▼
Net Income
-$17M
-30.5% ▼
EPS (Diluted)
$-0.16
-23.1% ▼
EBITDA
-$16M
-19.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $18M | $23M | $26M | $28M | $32M |
| YoY Growth | +20.6% | +31.1% | +13.4% | +4.7% | +17.2% |
| Cost of Revenue | $15M | $17M | $23M | $10M | $34M |
| Gross Profit | $3M | $6M | $16M | $18M | -$1M |
| Gross Margin | 18.1% | 25.6% | 61.1% | 65.0% | -4.5% |
| R&D Expenses | $2M | $3M | $4M | $365K | $615K |
| SG&A Expenses | $8M | $10M | $10M | $25M | $16M |
| Operating Expenses | $10M | $13M | $14M | $32M | $17M |
| Operating Income | -$6M | -$7M | -$5M | -$14M | -$18M |
| Operating Margin | -36.3% | -31.4% | -20.0% | -52.0% | -56.2% |
| Interest Expense | $89K | $266K | $216K | $319K | $626K |
| Income Before Tax | -$7M | -$8M | -$4M | -$13M | -$18M |
| Tax Expense | $693K | $582K | $511K | $126K | -$637K |
| Net Income | -$5M | -$7M | -$5M | -$13M | -$17M |
| Net Margin | -28.5% | -28.5% | -17.8% | -47.9% | -53.3% |
| EPS (Diluted) | $-0.06 | $-0.07 | $-0.05 | $-0.13 | $-0.16 |
| EBITDA | -$6M | -$6M | -$4M | -$14M | -$16M |
| Shares Outstanding | 90M | 92M | 93M | 103M | 110M |